The CTH-300/CTH-301 trials are investigating the safety and effectiveness of an oral, sublingual (under the tongue) therapy for patients with Parkinson’s disease who are experiencing motor symptoms known as OFF episodes.
If you have been diagnosed with Parkinson’s disease, are currently taking medication for Parkinson’s disease and experience at least one OFF episode per day, you may be eligible to participate in these trials.
View eligibility requirements here.
Learn More